In addition, recent analysis of data from the LUX-LUNG 3 and LUX-LUNG 6 trials has shown that in patients with exon 19 deletions (the commonest sensitising EGFR mutation), afatinib significantly prolongs overall survival in the first-line setting in stage IIIB-IV NSCLC when compared with doublet chemotherapy [3, 4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.